Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with the FDA in the first half of 2022 to discuss a proposed modified intent-to-treat efficacy analysis for AP-013, its second pivotal trial. “We […]

As the Ukraine crisis intensifies, CFOs across industries have been scrambling to keep up with fast-changing sanctions against Russia, assess and manage their corporate risk and make sure they have hardened defenses against the increased threats of cyber attacks. The financial fallout is gaining momentum. The U.S. and a coalition of G-7 nations joined together […]

FDA approves first drug-eluting contact lens The FDA has approved ACUVUE Theravision with Ketotifen (Johnson & Johnson Vision) as the first drug-eluting, vision-correcting contact lens. According to the company’s press release, each lens contains 19 mcg of ketotifen, which is an antihistamine. This contact lens will be indicated for the prevention of ocular itch due […]